Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: a randomized controlled trial

BMC Complementary and Alternative Medicine

Research Article

Hongbing Wang¹  Shengsheng Zhang¹  Luqing Zhao¹  Lin Tao¹  Tao Zhou¹  Chuijie Wang²  Hong Shen³  Suiping Huang⁴  Wei Wei⁵ 

[1] Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, No. 23 Meishuguan Back Street, 100010, Dongcheng District, Beijing, China;The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, 110033, Huanggu District, Shenyang, China;The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, No. 155 Hanzhong Street, 210029, Jianye District, Nanjing, China;The Second Affiliated Hospital of Guangdong University of Traditional Chinese Medicine, No. 111 Dade Street, 510120, Baiyun District, Guangzhou, China;Wangjing Hospital, Huajiadi Street, 100102, Chaoyang District, Beijing, China;

关键词: Functional dyspepsia;    Chinese herbal medicine;    Modified LiuJunZi decoction;    Randomized controlled trial;   

DOI  :  10.1186/1472-6882-13-54

 received in 2012-06-07, accepted in 2013-02-26,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundChinese herbal medicine (CHM) has been used in China and some other countries for the treatment of patients with functional dyspepsia (FD). However, controlled studies supporting the efficacy of such treatments in patients with FD are lacking. In this trial, we aimed to assess the efficacy and safety of modified LiuJunZi decoction in patients with FD of spleen-deficiency and qi-stagnation syndrome.MethodsWe performed a randomized, double-blind, placebo-controlled trial with patients from five centers. Patients with FD of spleen-deficiency and qi-stagnation syndrome (n = 160) were randomly assigned to groups given CHM modified LiuJunZi decoction or placebo in a 2:1 ratio. Herbal or placebo granules were dissolved in 300 ml of boiled water cooled to 70°C. Patients in both groups were administered 150 ml (50°C) twice daily. The trial included a 4-week treatment period and a 4-week follow-up period. The primary outcomes were dyspepsia symptom scores, measured by the total dyspepsia symptom scale and the single dyspepsia symptom scale at weeks 0, 1, 2, 3, 4 and 8. The secondary outcome was the change of radiopaque barium markers emptied from the stomach between week 0 and week 4 of treatment.ResultsCompared with patients in the placebo group, patients in the CHM group showed significant improvements according to the scores of total dyspepsia symptoms and single dyspepsia symptoms obtained from patients (P < 0.01) and investigators (P < 0.01). They also showed an improvement in the number of radiopaque barium markers emptied from the stomach (P < 0.05).ConclusionsCHM modified LiuJunZi decoction appears to offer symptomatic improvement in patients with FD of spleen-deficiency and qi-stagnation syndrome.Trial registrationChinese Clinical Trial Registry (ChiCTR): http://ChiCTR-TRC-10001074

【 授权许可】

CC BY   
© Zhang et al; licensee BioMed Central Ltd. 2013